NCT03359850: Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic uncontrolled brain or leptomeningeal metastases

Comments are closed.

Up ↑